Accelerated Approval and Confirmatory Trials

Accelerated approval, originally the subpart H regulations of 1992 and now codified in section 506(c) of the Federal Food, Drug, and Cosmetic Act, permits approval for a serious or life-threatening condition on a surrogate endpoint reasonably likely to predict clinical benefit, or on an intermediate clinical endpoint. The benefit is not demonstrated at the point of approval; it is predicted, and the sponsor owes confirmatory evidence afterwards.

Confirmation has historically been the weak half of the bargain. The Food and Drug Omnibus Reform Act of 2022 gave FDA authority to require that confirmatory trials be under way before approval and streamlined the procedure for withdrawing an approval when those trials fail or stall, which is why withdrawals are now more visible than they once were. Most accelerated approvals are oncology; the pathway is uncommon for metabolic peptides, whose trials read out on weight or HbA1c directly. Whether a given product still carries an unconverted accelerated approval changes over time and is tracked by FDA.

For anyone weighing evidence, the pathway matters more than the word approved. An accelerated approval says a surrogate moved and that FDA judged the movement likely to matter, not that patients lived longer or better. Two drugs both described as FDA-approved can sit on opposite sides of that line, and the gap between them is the gap between a demonstrated and a predicted outcome.

The failure mode is citing accelerated approval as though it closed the question, together with the mirror error of treating a withdrawal as scandal rather than as the mechanism working. The European conditional marketing authorisation operates on similar logic with annual renewal, and the two agencies do not always reach the same view of the same surrogate.